Locations
Vancouver, BC, Canada · north vancouver, bc, canada · North Vancouver, BC, Canada
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2015
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia in people with diabetes. Their unique technology targets somatostatin receptors in the pancreas, offering a preventative solution to a critical unmet medical need in diabetes management. With over 422 million people affected by diabetes globally, Zucara's approach aims to improve patient health and quality of life by addressing the life-threatening risks associated with hypoglycemia. The company has successfully progressed its lead drug candidate, ZT-01, through preclinical and clinical development, supported by significant funding and partnerships, positioning itself as a leader in diabetes treatment innovation.
Something looks off?